Amarin reported $-1.22M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amarin USD -1.22M 6.51M Dec/2025
AstraZeneca USD 3.12B 610M Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
DBV Technologies USD -64.5M 16.9M Sep/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026